KYMERA THERAPEUTICS
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
KYMERA THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kymeratx.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
604 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Wordpress Plugins
Similar Organizations
Abata Therapeutics
Abata Therapeutics is a biotech company.
Allay Therapeutics
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Casma Therapeutics
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines.
Freeline
Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Mahana Therapeutics
Mahana Therapeutics is a developer of digital treatments for people living with gastrointestinal conditions.
Neogene Therapeutics
Neogene Therapeutics is a biotech company providing cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Seer
Seer is a biotechnology company that offers tools and solutions related to the field of proteomics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
T. Rowe Price
T. Rowe Price investment in Post-IPO Equity - Kymera Therapeutics
Redmile Group
Redmile Group investment in Post-IPO Equity - Kymera Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Kymera Therapeutics
Avoro Capital Advisors
Avoro Capital Advisors investment in Post-IPO Equity - Kymera Therapeutics
Rock Springs Capital
Rock Springs Capital investment in Post-IPO Equity - Kymera Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - Kymera Therapeutics
Solasta Ventures
Solasta Ventures investment in Series C - Kymera Therapeutics
Redmile Group
Redmile Group investment in Series C - Kymera Therapeutics
BlackRock
BlackRock investment in Series C - Kymera Therapeutics
Bessemer Venture Partners
Bessemer Venture Partners investment in Series C - Kymera Therapeutics
Key Employee Changes
Official Site Inspections
http://www.kymeratx.com Semrush global rank: 1.88 M Semrush visits lastest month: 11.68 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Kymera Therapeutics"
Our Company - Kymera Therapeutics
Mar 31, 2023 Leading the Charge for Transformative Therapeutics . Kymera is a clinical-stage biotechnology company working to reinvent the treatment of human disease through the development of innovative, highly differentiated medicines …See details»
SEC Filing | Kymera Therapeutics, Inc. - investors.kymeratx.com
Incorporation or organization) (I.R.S. Employer Identification No.) 500 North Beacon Street, 4th Floor. Watertown, Massachusetts. 02472 (Address of principal executive offices) (Zip Code) …See details»
About Us - Kymera Therapeutics
500 North Beacon Street, 4th Floor, Watertown, MA 02472 © 2025 Kymera Therapeutics, Inc. All Rights Reserved.See details»
Kymera Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It …See details»
Kymera Therapeutics Announces Fourth Quarter and Full Year …
To access the conference call via phone, please dial +1 (833) 630-2127 or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the event will be …See details»
Kymera Overview | Kymera Therapeutics, Inc.
Kymera Overview | Kymera Therapeutics, Inc.See details»
Kymeratx - Company Profile - Tracxn
Feb 21, 2025 Kymeratx - Developer of small molecule protein degraders for multiple disorders. Public Company. Raised a total funding of $197M over 4 rounds from 24 investors. Founded …See details»
Working at Kymera - Kymera Therapeutics
Our Clinical Development group has played a major role transforming the company from a research organization into one with multiple programs in the clinic. With a newer modality, the …See details»
Kymera Therapeutics - Overview, News & Similar companies
Jun 1, 2024 Kymera Therapeutics contact info: Phone number: (857) 285-5300 Website: www.kymeratx.com What does Kymera Therapeutics do? Kymera Therapeutics (Nasdaq: …See details»
Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating …
WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein …See details»
Kymera Therapeutics Appoints Healthcare Industry Leader
Jan 18, 2022 [email protected] 857-285-5300. Chris Brinzey Managing Director, Westwicke [email protected] 339-970-2843. Media Contact: Tyler Gagnon …See details»
Kymeratx - Raised $197M Funding from 24 investors - Tracxn
Mar 23, 2025 Kymeratx has raised a total funding of $197M over 4 rounds from 24 investors. Investors include Foresite Capital, Atlas Venture and 22 others. Their latest funding round was …See details»
Kymera Cares - Kymera Therapeutics
Kymera is committed to giving back to the communities where we live and work. Our annual month of service supports employees as they deliver food, prepare backpacks for …See details»
Release Details - Kymera Therapeutics, Inc.
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of …See details»
Kymera Therapeutics - LeadIQ
Aug 19, 2024 [email protected]: [email protected]: 5%. [email protected]: [email protected]: 3%. See more formats. Frequently Asked Questions Where is Kymera …See details»
Our Approach - Kymera Therapeutics
Pioneering Targeted Protein Degradation to Invent New Medicines . Targeted protein degradation (TPD) is a powerful drug modality that harnesses the cell’s existing protein disposal and …See details»
Toyota Announces Executive Changes - Toyota USA Newsroom
PLANO, TX (March 26, 2025) – Toyota Motor North America (TMNA) has announced a revised leadership structure along with executive changes effective April 1, 2025: Structural Changes …See details»
Pipeline - Kymera Therapeutics
Kymera’s pipeline is focused on addressing disease targets where there is significant patient need and where we believe protein degradation is the only or best way to improve the standard of care.See details»
Release Details - Kymera Therapeutics, Inc.
Jun 30, 2023 [email protected] 857-285-5300 Justine Koenigsberg Vice President, Investor Relations [email protected] 857-285-5300: Media Contact: Todd Cooper …See details»
Kymera Therapeutics Announces Fourth Quarter and Full Year …
Dec 31, 2024 KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected …See details»